FDA has recently revised Form 356h: Application to Market a New or Abbreviated New Drug or Biologic for Human Use and Form 1571: Investigational New Drug Application (IND) to align with FDA User Fee requirements as well as make other improvements to data quality and ease of use.
These forms are required to be submitted with NDAs, ANDAs, BLAs and INDs. FDA uses this information in the review process and companies should be aware of these updates and are required to use the most current version of these forms.
Companies need to use the most recent update to Forms 356h and 1571 in their submissions.
View referenced article
Author(s)
Related Insights
May 18, 2026
Foley Viewpoints
Wealth Tax Watch: Washington’s Millionaires Tax Will Not Go to the Voters, and Updates to New York’s Taxes on Real Estate
In our third installment of recapping states’ efforts to impose new taxes on high-net-worth individuals, we want to provide updates on…
May 15, 2026
Foley Viewpoints
NMTC Summit Takeaways: Key Themes Foley Heard in Miami
Foley’s New Markets Tax Credit (NMTC) team attended the recent Cohn Reznick NMTC Summit in Miami, where community development entities…
May 11, 2026
Foley Viewpoints
Rebuilding the Thymus: AI, Regenerative Medicine, and the Emerging Biotechnology of Immune Longevity
This recent Nature article by Bernatz et al. particularly piqued my interest because years ago I did scientific research on thymic…